Cytokinetics EVP, Chief Commercial Officer Andrew Callos sells 14,000 common shares for $1.12 millionPUBT·2 days ago, 03:27 PMCYTK-4.09%
Surviving Outside the Monopolies: The Non-Aggregation Logic of Physical and Niche MarketsGlobal Report·Jul 30 at 04:14 AMFAST+2.25%ADVB-20.63%
Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales | CYTK Stock NewsStockTitan·Jul 29 at 09:20 PMCYTK-4.09%
The Barbell Economy: Capital Aggregation and Vertical Specialization in 2026Global Report·Jul 29 at 04:18 AMCCOJY0.00%PUMP+2.59%
Is Cytokinetics (CYTK) Cheap Or Has Its Cardiac Growth Story Already Been Priced In?Simplywall·Jul 28 at 02:23 AMCYTK-4.09%
Cytokinetics CEO Robert I. Blum disposes of 7,500 common shares for $606,525PUBT·Jul 27 at 03:34 PMCYTK-4.09%
New AI ETF Bets on Healthcare's $9 Trillion Opportunitybenzinga_article·Jul 24 at 02:08 PMHLTH-0.60%CYTK-4.09%
Cytokinetics EVP R&D Malik Fady Ibraham disposes of 3,500 common shares for $282,065PUBT·Jul 23 at 03:10 PMCYTK-4.09%
Cytokinetics to Announce Second Quarter Results on August 6, 2026Unusual Whales·Jul 23 at 03:02 PMCYTK-4.09%
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CYTK Stock NewsStockTitan·Jul 17 at 07:00 AMCYTK-4.09%
Cytokinetics (CYTK) Could Be 22% Undervalued On Its Growth NarrativeSimplywall·Jul 15 at 08:08 AMCYTK-4.09%
